中國生物科技服務(08037.HK)預計年度盈利不少於1.40億港元
格隆匯 3 月 1日丨中國生物科技服務(08037.HK)公佈,預期集團於2020年年度將會錄得不少於1.40億港元的溢利淨額,而於2019年同期則錄得虧損淨額約為1.07億港元。
董事會認為,預期由2019年年度的虧損淨額扭轉為2020年年度的溢利淨額,主要是由於以下各項所致:(i)香港於七月中旬出現第三波新冠肺炎疫情,導致對COVID-19檢測服務的需求大幅增加;(ii)集團為在普及社區檢測計劃為香港市民提供COVID-19檢測服務的參與者之一;(iii)透過策略性發展及市場推廣及宣傳活動,以致提供醫學實驗室檢測服務及健康檢查服務分部之收入及毛利出現強勁增長;及(iv)提供醫學實驗室檢測服務及健康檢查服務分部於2020年年度並無錄得無形資產減值虧損(2019年年度:2883.8萬港元)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.